euro api
Paris – 16 October 2024 – Olivier Fallout has been appointed Chief Financial Officer of EUROAPI with effect from 17 October 2024 and will become a member of the Executive Board. He will succeed Evelyn Nguyen and will remain with the company until the end of October to ensure a smooth transition.
“We are pleased to welcome Olivier, an experienced Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in the implementation of our FOCUS-27 transformation project.” said Ludwig de Moto, CEO of EUROAPI. “The entire company and Board of Directors would like to express our sincere gratitude to Evelyn for her commitment to ensuring that our strategic plans are funded.”
Olivier Falut joins EUROAPI with nearly 30 years of experience in industrial sector management and finance. Throughout his career, he held a variety of financial positions at public and private companies, including Fareba, Limagrain (including Vilmorin & Cie), Lactalis, and Bell.
“We are excited to join EUROAPI and participate in the implementation of the FOCUS-27 transformation plan. This new economic dynamic allows us to execute large-scale projects and sustain our organization for years to come. We will be able to ensure the growth that is possible,” said Olivier Fallout.
Olivier Fallut’s career
Olivier Falut began his career in the financial audit department, primarily at Ernst & Young in France and then in the United States. He joined Bosch France in 2001 as Accounting Director and began his career at Bell in 2003 as Accounting Director. Joined Oberthur Technologies in 2008 as CFO of major business units, then moved to Lactalis as Group Head (2012-2017) Financial Management. Since 2017, he has held CFO positions at various companies including Sodiaal, Segula Technologies, Limagran, and Fareva.
Olivier Falut is a graduate of ESSEC Business School with a Master’s degree in Business Law. He also graduated from the French bar exam.
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet the needs of customers and patients around the world. We are a leading active pharmaceutical ingredient company with approximately 200 products in our portfolio and offer a broad range of technologies while developing innovative molecules through our contract development and manufacturing organization (CDMO) activities.
Taking action for health by providing access to essential treatments inspires our 3,650 employees every day. EUROAPI has strong R&D capabilities and six manufacturing locations, all located in Europe, ensuring the highest quality API manufacturing and supplying customers in over 80 countries. EUROAPI is listed on Euronext Paris. ISIN: FR0014008VX5;Ticker: EAPI). For more information, please visit www.euroapi.com and follow us on LinkedIn.
story continues
Forward-looking statements
Certain information contained in this press release is forward-looking and not historical data. These forward-looking statements express opinions, projections and Based on current assumptions. , operations, future service or product development, and potential. Forward-looking statements are typically identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Masu. Forward-looking statements and information are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, many of which are difficult to predict and which generally affect the Group’s performance. are beyond its control and may have real consequences. , that our performance or results or the results of sector or other events may differ materially from those described or implied in these forward-looking statements. These risks and uncertainties are set out and detailed in Chapter 3 “Risk Factors” of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des Marchés Financiers, AMF) on April 5, 2024. Includes what is listed. These forward-looking statements include: They speak only as of the date of this press release, and we do not intend to update any forward-looking statements contained in this press release to reflect changes in expectations, events, conditions or circumstances affecting our expectations. expressly disclaims any obligation or undertaking to publish any changes or amendments. These forward-looking statements are based on.
attachment
